绥美凯效果怎样呢？

It has been approved in more than 100 countries and recommended by many authoritative academic institutions in Europe and the United States as a first-line treatment drug for newly treated AIDS patients. In January 2018, Inbec, an innovative AIDS treatment drug developed by ViiV Healthcare, a joint venture of the British multinational pharmaceutical company GlaxoSmithKline (GSK), officially launched in the Chinese market.

Inbec contains three ingredients: abacavir, lamivudine and dolutegravir. Abacavir and lamivudine are nucleoside reverse transcriptase inhibitors (NRTIs); dolutegravir is an integrase inhibitor (INIs). Existing research shows that one year (48 weeks) after HIV-infected patients were treated with Inbec, 93% of the infected people's viral load became negative.

Different ingredients of Suimeikan exert different effects.

Dolutegravir inhibits HIV integrase by binding to the integrase active site and blocking the strand transfer step of reverse transcription deoxyribonucleic acid (DNA) integration (a key step in the HIV replication cycle).

Abacavir is a carbocyclic synthetic nucleoside analogue. Abacavir is converted into the active metabolite carbavir triphosphate (CBV-TP), a deoxyguanosine-5'-triphosphate (dGTP) analogue, under the action of intracellular enzymes. CBV-TP inhibits the activity of HIV-1 reverse transcriptase (RT) by competing with the natural substrate dGTP and inserting into viral DNA.

Lamivudine is a synthetic nucleoside analogue. Lamivudine is phosphorylated in cells to generate the active 5-triphosphate metabolite, lamivudine triphosphate (3TC-TP). The main mode of action of 3T-CTP is to terminate DNA chain synthesis by inserting nucleotide analogs, thereby inhibiting RT activity.

Because ingredients may cause hypersensitivity reactions, patients should be screened for the HLA-B*5701 allele before starting treatment with abacavir-containing products, regardless of race.